BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 31, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2009

View Archived Issues

Odanacatib increases BMD in ovariectomized monkeys and postmenopausal women

Read More

EMEA approves ALK-Abello's Grazax as disease-modifying allergy treatment

Read More

Achillion completes phase Ia of phase Ia/b clinical trial of ACH-1625 in hepatitis C

Read More

Antitumor effect of TH-302 plus gemcitabine, docetaxel or pemetrexed seen in phase Ib trial

Read More

MT-110 safe and biologically active in phase I advanced solid tumors trial

Read More

Taisho claims mgluR5 agonists for the treatment of psychiatric disorders

Read More

Glucokinase activators for the treatment of diabetes disclosed by Daiichi Sankyo

Read More

Sanofi-aventis completes enrollment in phase III angiogenesis trial of NV1-FGF

Read More

European CHMP issues positive opinion for Januvia and Janumet for type 2 diabetes

Read More

Boehringer concludes phase III clinical trials of linagliptin in type 2 diabetes

Read More

European CHMP issues positive opinion for Pandemrix, GSK's pandemic H1N1 vaccine

Read More

Addex completes enrollment in phase IIb trial in gastroesophageal reflux disease

Read More

NCI awards phase II bridge grant to Altor BioScience to develop ALT-801

Read More

Wyeth's pneumococcal vaccine Prevenar 13 receives positive opinion for E.U. approval

Read More

Novartis' QAB-149 recommended for approval in the E.U. for treatment of COPD

Read More

European CHMP issues positive opinion for sanofi-aventis' Multaq in atrial fibrillation

Read More

Momenta reports results from EMINENCE phase II trial of anticoagulant M-118

Read More

University of Texas initiates enrollment in phase II trial of Oncolytics Biotech's Reolysin

Read More

PM-181104 shows antimicrobial activity in mouse models of MRSA and VRE infections

Read More

Hib-MenCY-TT candidate vaccine is immunogenic and well tolerated as 4th dose in infants

Read More

Synthetic vaccine SFV2/NAM1 displays broadly reactive immunity against influenza

Read More

HVJ envelope to enter clinical study for melanoma

Read More

Vitae Pharmaceuticals discovers 11beta-HSD1 inhibitors for the treatment of obesity

Read More

NS5B inhibitors for the treatment of HCV infection identified by Roche

Read More

AstraZeneca granted approval for Seroquel XR and Seroquel in Europe for bipolar disorder

Read More

Sciele submits NDA to FDA for glycopyrrolate to treat drooling in pediatric patients

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing